Search results for "GOLFIG"

showing 2 items of 2 documents

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

2019

Background: GOLFIG is a chemo-immunotherapy regimen established in preclinical models that combines gemcitabine + FOLFOX (fluoropyrimidine backbone coupled to oxaliplatin) poly-chemotherapy with low-dose s. c. recombinant interleukin-2 (rIL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF). Promising antitumor effects in metastatic colorectal cancer (mCRC) patients were obtained in previous phase II and III trials. Here we report the results of 15 years of follow-up. Methods: This is a multi-institutional retrospective analysis including 179 mCRC patients receiving GOLFIG regimen between June 2002 and June 2018. Sixty-two of them received the treatment as frontline (enrolled …

0301 basic medicineOncologymedicine.medical_specialtyCancer ResearchColorectal cancermedicine.medical_treatmentcolorectal cancerchemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineFOLFOXInternal medicineMedicineAdverse effectOriginal ResearchChemotherapybusiness.industryHazard ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasechemotherapy; colorectal cancer; GOLFIG; immunotherapy; metastatic; phase III clinical trial; real-world medicineGemcitabineOxaliplatinmetastaticRegimen030104 developmental biologyOncology030220 oncology & carcinogenesisGOLFIGphase III clinical trialimmunotherapyreal-world medicinebusinessmedicine.drug
researchProduct

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorect…

2015

ABSTRACT: Thymidylate synthase (TS) is a tumor-associated enzyme critical for DNA replication and main 5′-fluorouracil (5′-FU) target. TSPP/VAC1 is a multi-arm trial phase-Ib trial program aimed to investigate the toxicity and biomodulatory activity of a poly-epitope-peptide vaccine to TS (TSPP) in cancer patients (pts). Here, we present the results of the TSPP/VAC1/arm C trial aimed to evaluate TSPP in combination with chemo-immunotherapy in pretreated metastatic colo-rectal cancer (mCRC) pts. Twenty-nine pts, 14 males and 15 females, received poly-chemotherapy with gemcitabine [GEM; 1,000 mg/sqm, day-1], oxaliplatin [OX; 80 mg/sqm, day-2], levofolinate [100 mg/sqm, days 1–2], bolus/infusi…

0301 basic medicinemedicine.medical_specialtyepitope peptidesImmunologyGOLFIG chemo-immunotherapythymidylate synthaseGastroenterologyThymidylate synthaseCTLs03 medical and health sciences0302 clinical medicineBolus (medicine)SargramostimInternal medicinepeptide vaccineMedicineImmunology and AllergyOriginal Researchbiologybusiness.industryColon cancer; CTLs; epitope peptides; GOLFIG chemo-immunotherapy; peptide vaccine; thymidylate synthase; Immunology and Allergy; Oncology; ImmunologyGemcitabineOxaliplatinColon cancerRegimen030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisConcomitantImmunologyCTLbiology.proteinbusinessepitope peptidemedicine.drug
researchProduct